瘤细胞通过上调调节PD-1表达来抑制ILC2s的激活
Chaoyun Yin1,2, Yani Pa2, Guangyu Li2
1Department of Emergency Medicine, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, P. R. China.
Immunopharmacology and immunotoxicology
|April 28, 2024
概括
编程细胞死亡-1 (PD-1) 上调抑制肺癌中的先天性淋巴细胞 (ILC2). 用抗PD-1疗法阻止PD-1恢复ILC2功能并抑制瘤生长,提供了一种新的免疫疗法策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 编程细胞死亡-1 (PD-1) 和编程细胞死亡联体-1 (PD-L1) 对免疫细胞的相互作用可以阻碍抗瘤反应.
- 了解这些相互作用对于提高癌症免疫疗法疗效至关重要.
研究的目的:
- 调查PD-1表达在传入肺癌的II型先天性淋巴细胞 (ILC2) 中的作用.
- 探索针对PD-1/PD-L1轴以增强基于ILC2的癌症免疫治疗的潜力.
主要方法:
- 对肺癌透性ILC2s中的PD-1表达的分析.
- 在体外共同培养实验中使用瘤细胞和抗PD-1治疗.
- 在体内研究中,使用携带LCL的裸体小鼠接受了抗PD-1治疗.
主要成果:
- 对于透到肺癌的ILC2s,PD-1的调控高度提升,抑制了它们的激活和功能.
- 抗PD-1治疗恢复了ILC2细胞因子的分泌和抗瘤活性在体外.
- 在体内,抗PD-1治疗促进了ILC2的激活,抑制了瘤的生长.
结论:
- 发现了一种涉及天生的免疫细胞的新型PD-1/PD-L1调节机制.
- 针对这一轴为基于ILC2的免疫疗法在癌症治疗中提供了一个有希望的策略.
更多相关视频
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


